{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:28:11Z","timestamp":1770899291006,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09120012110070"],"award-info":[{"award-number":["09120012110070"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09120012110070"],"award-info":[{"award-number":["09120012110070"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09120012110070"],"award-info":[{"award-number":["09120012110070"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Disease criteria for multiple sclerosis (MS) have changed significantly over the past three decades. The development of biomarkers, particularly MRI, has played an essential role in this process. These changes can lead to several broader implications, which are not always intended or recognized. However, they can have a major impact on patients, healthcare and society. We investigated the changing disease criteria, explored the underlying motives and discuss their implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified all publications on MS diagnostic criteria between 1983 and 2024. Through conventional content analysis, we systematically examined the aims of each revision and identified the underlying problems and factors motivating these aims. Furthermore, we assessed the changes made to the content in each revision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since the transition from the Poser research criteria to the McDonald clinical criteria in 2001, there has been a significant change in the aims of the criteria, which has continued in subsequent McDonald revisions. Two explicit new aims were to integrate MRI into the diagnostic scheme and to reach an earlier diagnosis of MS whenever possible. Furthermore, the emphasis moved towards criteria that are easy to apply in everyday clinical practice, rather than being exclusively for research purposes. This shift is at least partially connected to the emergence of disease-modifying treatments, which have introduced new diagnostic and monitoring needs. Additionally, advancements in MRI research have contributed to this process. As a result, MRI has become central to the diagnostic criteria over the years, while clinical symptoms now play a much smaller role.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The shift in the criteria has several broader implications. It has a major impact on how MS is conceptualized as a disease and has expanded the disease spectrum to include new terms such as radiologically isolated syndrome (RIS). It also influences our understanding of the natural course of the disease and calls for a careful balance between early diagnosis and misdiagnosis. Awareness of the process of changes and their broader consequences can help balance the benefits and potential negative effects and helps critically frame the decisions of the 2024 revisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04641-x","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:45:14Z","timestamp":1769154314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolution of disease criteria in multiple sclerosis: underlying motives and broader implications"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-308X","authenticated-orcid":false,"given":"Kristofoor E.","family":"Leeuwenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart H.","family":"van der Molen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Boenink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edo","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"4641_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"4641_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"CM Poser","year":"1983","unstructured":"Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227\u201331. https:\/\/doi.org\/10.1002\/ana.410130302.","journal-title":"Ann Neurol"},{"key":"4641_CR3","unstructured":"Mishina E, Agyeman A, Amur S, et al. Response biomarker (Chapter). BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver spring (MD): food and drug administration (US). Co-published by National Institutes of Health (US); 2021. pp. 15\u2013 18. https:\/\/www.researchgate.net\/publication\/356567685_BEST_Biomarkers_EndpointS_and_other_Tools_Resource_Chapter_Response_Biomarke"},{"key":"4641_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.msard.2017.08.016","volume":"17","author":"B Yamout","year":"2017","unstructured":"Yamout B, Al Khawajah M. Radiologically isolated syndrome and multiple sclerosis. Mult Scler Relat Disord. 2017;17:234\u20137. https:\/\/doi.org\/10.1016\/j.msard.2017.08.016.","journal-title":"Mult Scler Relat Disord"},{"key":"4641_CR5","doi-asserted-by":"publisher","unstructured":"Lloret A, Esteve D, Lloret MA, et al. When Does Alzheimer\u2019s Disease Really Start? The Role of Biomarkers. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20225536.","DOI":"10.3390\/ijms20225536"},{"key":"4641_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.0000000000009107","volume":"94","author":"AJ Espay","year":"2020","unstructured":"Espay AJ, Kalia LV, Gan-Or Z, et al. Disease modification and biomarker development in Parkinson disease: revision or reconstruction? Neurology. 2020;94:481\u201394. https:\/\/doi.org\/10.1212\/WNL.0000000000009107.","journal-title":"Neurology"},{"key":"4641_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/pme.10.41","volume":"7","author":"I Metzler","year":"2010","unstructured":"Metzler I. Biomarkers and their consequences for the biomedical profession: a social science perspective. Per Med. 2010;7:407\u201320. https:\/\/doi.org\/10.2217\/pme.10.41.","journal-title":"Per Med"},{"key":"4641_CR8","doi-asserted-by":"publisher","first-page":"e70133","DOI":"10.1002\/alz.70133","volume":"21","author":"L Van der Molen","year":"2025","unstructured":"Van der Molen L, Boenink M, Van Lente H, et al. Changing definitions of disease: transformations in the diagnostic criteria for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2025;21:e70133. https:\/\/doi.org\/10.1002\/alz.70133.","journal-title":"Alzheimer\u2019s Dement"},{"key":"4641_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1754-9485.2012.02448.x","volume":"56","author":"L Josey","year":"2012","unstructured":"Josey L, Curley M, Jafari Mousavi F, Taylor BV, Lucas R, Coulthard A. Imaging and diagnostic criteria for multiple sclerosis: are we there yet? J Med Imaging Radiat Oncol. 2012;56:588\u201393. https:\/\/doi.org\/10.1111\/j.1754-9485.2012.02448.x.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"4641_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","volume":"122","author":"GA Schumacher","year":"1965","unstructured":"Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552\u201368. https:\/\/doi.org\/10.1111\/j.1749-6632.1965.tb20235.x.","journal-title":"Ann N Y Acad Sci"},{"key":"4641_CR11","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Frenay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24:850\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4.","journal-title":"Lancet Neurol"},{"key":"4641_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"key":"4641_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121\u20137. https:\/\/doi.org\/10.1002\/ana.1032.","journal-title":"Ann Neurol"},{"key":"4641_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann Neurol. 2005;58:840\u20136. https:\/\/doi.org\/10.1002\/ana.20703.","journal-title":"Ann Neurol"},{"key":"4641_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366.","journal-title":"Ann Neurol"},{"issue":"Pt 11","key":"4641_CR16","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","volume":"120","author":"F Barkhof","year":"1997","unstructured":"Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059\u201369. https:\/\/doi.org\/10.1093\/brain\/120.11.2059.","journal-title":"Brain"},{"key":"4641_CR17","first-page":"702","volume":"21","author":"M Tintore","year":"2000","unstructured":"Tintore M, Rovira A, Mart\u00ednez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000;21:702\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"Suppl 2","key":"4641_CR18","first-page":"5","volume":"23","author":"RS Allison","year":"1954","unstructured":"Allison RS, Millar JHD. Prevalence of disseminated sclerosis. Ulster Med J. 1954;23(Suppl 2):5\u201327.","journal-title":"Ulster Med J"},{"key":"4641_CR19","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/1352458516675039","volume":"23","author":"A Kavaliunas","year":"2017","unstructured":"Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23:1233\u201340. https:\/\/doi.org\/10.1177\/1352458516675039.","journal-title":"Mult Scler"},{"key":"4641_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000013016","volume":"98","author":"M Filippi","year":"2022","unstructured":"Filippi M, Preziosa P, Meani A, et al. Performance of the 2017 and 2010 revised McDonald criteria in predicting MS diagnosis after a clinically isolated syndrome: A MAGNIMS study. Neurology. 2022;98:e1\u201314. https:\/\/doi.org\/10.1212\/WNL.0000000000013016.","journal-title":"Neurology"},{"key":"4641_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","volume":"15","author":"M Filippi","year":"2016","unstructured":"Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292\u2013303. https:\/\/doi.org\/10.1016\/S1474-4422(15)00393-2.","journal-title":"Lancet Neurol"},{"key":"4641_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1053\/j.gastro.2021.07.037","volume":"161","author":"DA Drossman","year":"2021","unstructured":"Drossman DA, Chang L, Deutsch JK, et al. A review of the evidence and recommendations on communication skills and the Patient-Provider relationship: A Rome foundation working team report. Gastroenterology. 2021;161:1670\u2013e16881677. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.037.","journal-title":"Gastroenterology"},{"key":"4641_CR23","doi-asserted-by":"publisher","first-page":"e1641","DOI":"10.1212\/WNL.0000000000012726","volume":"97","author":"M Tintore","year":"2021","unstructured":"Tintore M, Cobo-Calvo A, Carbonell P, et al. Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology. 2021;97:e1641\u201352. https:\/\/doi.org\/10.1212\/WNL.0000000000012726.","journal-title":"Neurology"},{"key":"4641_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e318277d144","volume":"79","author":"D Selchen","year":"2012","unstructured":"Selchen D, Bhan V, Blevins G, et al. MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary. Neurology. 2012;79:S1\u201315. https:\/\/doi.org\/10.1212\/WNL.0b013e318277d144.","journal-title":"Neurology"},{"key":"4641_CR25","doi-asserted-by":"publisher","first-page":"104217","DOI":"10.1016\/j.msard.2022.104217","volume":"68","author":"A Hosseinzadeh","year":"2022","unstructured":"Hosseinzadeh A. Dramatic changes in multiple sclerosis incidence in Iran May be related to \u2018Will Rogers phenomenon\u2019. Mult Scler Relat Disord. 2022;68:104217. https:\/\/doi.org\/10.1016\/j.msard.2022.104217.","journal-title":"Mult Scler Relat Disord"},{"issue":"Suppl 1","key":"4641_CR26","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/S0022-510X(09)71300-0","volume":"287","author":"MP Sormani","year":"2009","unstructured":"Sormani MP. The will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci. 2009;287(Suppl 1):S46\u201339. https:\/\/doi.org\/10.1016\/S0022-510X(09)71300-0.","journal-title":"J Neurol Sci"},{"issue":"4","key":"4641_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ana.21464","volume":"64","author":"MP Sormani","year":"2008","unstructured":"Sormani MP, Tintore M, Rovaris M, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64(4):428\u201333. https:\/\/doi.org\/10.1002\/ana.21464.","journal-title":"Ann Neurol"},{"key":"4641_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.msard.2011.08.002","volume":"1","author":"A Gafson","year":"2012","unstructured":"Gafson A, Giovannoni G, Hawkes CH. The diagnostic criteria for multiple sclerosis: from Charcot to McDonald. Mult Scler Relat Disord. 2012;1:9\u201314. https:\/\/doi.org\/10.1016\/j.msard.2011.08.002.","journal-title":"Mult Scler Relat Disord"},{"key":"4641_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/1352458510362441","volume":"16","author":"CH Hawkes","year":"2010","unstructured":"Hawkes CH, Giovannoni G. The McDonald criteria for multiple sclerosis: time for clarification. Mult Scler. 2010;16:566\u201375. https:\/\/doi.org\/10.1177\/1352458510362441.","journal-title":"Mult Scler"},{"issue":"11","key":"4641_CR30","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamaneurol.2018.2160","volume":"75","author":"RM Van de Vuurst de Vries","year":"2018","unstructured":"Van de Vuurst de Vries RM, Mescheriakova JY, Wong YYM, et al. Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated synrome. JAMA Neurol. 2018;75(11):1392\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2160.","journal-title":"JAMA Neurol"},{"issue":"1","key":"4641_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1212\/WNL.0000000000006584","volume":"92","author":"WJ Brownlee","year":"2019","unstructured":"Brownlee WJ. Misdiagnosis of multiple sclerosis: if you have a hammer, everything looks like a nail? Neurology. 2019;92(1):15\u20136. https:\/\/doi.org\/10.1212\/WNL.0000000000006584.","journal-title":"Neurology"},{"key":"4641_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nrneurol.2017.106","volume":"13","author":"AJ Solomon","year":"2017","unstructured":"Solomon AJ, Corboy JR. The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nat Rev Neurol. 2017;13:567\u201372. https:\/\/doi.org\/10.1038\/nrneurol.2017.106.","journal-title":"Nat Rev Neurol"},{"issue":"11\u201312","key":"4641_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1177\/13524585241274527","volume":"30","author":"WE Z\u00fcrrer","year":"2024","unstructured":"Z\u00fcrrer WE, Cannon AE, Ilchenko DI, et al. Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 2024;30(11\u201312):1409\u201322. https:\/\/doi.org\/10.1177\/13524585241274527.","journal-title":"Mult Scler"},{"key":"4641_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1212\/WNL.0000000000003152","volume":"87","author":"AJ Solomon","year":"2016","unstructured":"Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016;87:1393\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000003152.","journal-title":"Neurology"},{"issue":"11","key":"4641_CR35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11910-024-01371-w","volume":"24","author":"NB Rjeily","year":"2024","unstructured":"Rjeily NB, Solomon AJ. Misdiagnosis of multiple sclerosis: Past, Present, and future. Curr Neurol Neurosci Rep. 2024;24(11):547\u201357. https:\/\/doi.org\/10.1007\/s11910-024-01371-w.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"4641_CR36","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","volume":"72","author":"DT Okuda","year":"2009","unstructured":"Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72:800\u20135. https:\/\/doi.org\/10.1212\/01.wnl.0000335764.14513.1a.","journal-title":"Neurology"},{"key":"4641_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1352458512451943","volume":"19","author":"T Granberg","year":"2013","unstructured":"Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S. Radiologically isolated syndrome\u2013incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler. 2013;19:271\u201380. https:\/\/doi.org\/10.1177\/1352458512451943.","journal-title":"Mult Scler"},{"key":"4641_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s11910-011-0213-z","volume":"11","author":"R Spain","year":"2011","unstructured":"Spain R, Bourdette D. The radiologically isolated syndrome: look (again) before you treat. Curr Neurol Neurosci Rep. 2011;11:498\u2013506. https:\/\/doi.org\/10.1007\/s11910-011-0213-z.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"4641_CR39","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1093\/brain\/awad07","volume":"1","author":"C Lebrun-Frenay","year":"2023","unstructured":"Lebrun-Frenay C, Okuda DT, Siva A, et al. The radiologically isolated syndrome: revised diagnostic criteria. Brain. 2023;1(8):3431\u201343. https:\/\/doi.org\/10.1093\/brain\/awad07.","journal-title":"Brain"},{"key":"4641_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.neurol.2016.04.004","volume":"172","author":"C Lebrun","year":"2016","unstructured":"Lebrun C, Cohen M, Clavelou P. Evaluation of quality of life and fatigue in radiologically isolated syndrome. Rev Neurol. 2016;172:392\u20135. https:\/\/doi.org\/10.1016\/j.neurol.2016.04.004.","journal-title":"Rev Neurol"},{"key":"4641_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/ana.25799","volume":"88","author":"C Lebrun-Frenay","year":"2020","unstructured":"Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT. Radiologically isolated syndrome: 10-Year risk estimate of a clinical event. Ann Neurol. 2020;88:407\u201317. https:\/\/doi.org\/10.1002\/ana.25799.","journal-title":"Ann Neurol"},{"issue":"11","key":"4641_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrneurol.2009.157","volume":"5","author":"DT Okuda","year":"2009","unstructured":"Okuda DT. Unanticipated demyelinating pathology of the CNS. Nat Rev Neurol. 2009;5(11):591\u20137. https:\/\/doi.org\/10.1038\/nrneurol.2009.157.","journal-title":"Nat Rev Neurol"},{"key":"4641_CR43","unstructured":"Multiple sclerosis in adults: management NICE guideline [NG220]. National Institute for Health and Care Excellence (NICE). Updated June 22. 2022. Accessed April 15. 2025. https:\/\/www.nice.org.uk\/guidance\/ng220."},{"key":"4641_CR44","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1468-1331.2006.01543.x","volume":"13","author":"M Filippi","year":"2006","unstructured":"Filippi M, Rocca MA, Arnold DL, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol. 2006;13:313\u201325. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01543.x.","journal-title":"Eur J Neurol"},{"key":"4641_CR45","unstructured":"Multiple Sclerosis (MS). Nederlandse Vereniging voor Neurologie. Kennisinstituut van de Federatie van Medische Specialisten. Updated November 11. 2023. Accessed April 15, 2025. https:\/\/richtlijnendatabase.nl\/richtlijn\/multiple_sclerose_ms\/startpagina_addendum_multiple_sclerose.html"},{"key":"4641_CR46","doi-asserted-by":"publisher","unstructured":"Rashid W, Ciccarelli O, Leary SM, Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance Pract Neurol., Gold R, Thompson AJ et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25:215\u2013237. https:\/\/doi.org\/10.1111\/ene.13536.","DOI":"10.1111\/ene.13536"},{"key":"4641_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25:215\u201337. https:\/\/doi.org\/10.1111\/ene.13536.","journal-title":"Eur J Neurol"},{"key":"4641_CR48","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1177\/1352458517727149","volume":"23","author":"C Lebrun","year":"2017","unstructured":"Lebrun C. Radiologically isolated syndrome should be treated with disease-modifying therapy - Commentary. Mult Scler. 2017;23:1821\u20133. https:\/\/doi.org\/10.1177\/1352458517727149.","journal-title":"Mult Scler"},{"key":"4641_CR49","doi-asserted-by":"publisher","first-page":"787160","DOI":"10.3389\/fneur.2022.787160","volume":"13","author":"MP Amato","year":"2022","unstructured":"Amato MP, De Stefano N, Inglese M, et al. Secondary prevention in radiologically isolated syndromes and prodromal stages of multiple sclerosis. Front Neurol. 2022;13:787160. https:\/\/doi.org\/10.3389\/fneur.2022.787160.","journal-title":"Front Neurol"},{"key":"4641_CR50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.26555","volume":"93","author":"DT Okuda","year":"2023","unstructured":"Okuda DT, Kantarci O, Lebrun-Fr\u00e9nay C, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol. 2023;93:604\u201314. https:\/\/doi.org\/10.1002\/ana.26555.","journal-title":"Ann Neurol"},{"key":"4641_CR51","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","volume":"80","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay C, Siva A, Sormani MP, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol. 2023;80:1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2815.","journal-title":"JAMA Neurol"},{"issue":"14","key":"4641_CR52","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1177\/13524585211002097","volume":"27","author":"F Barkhof","year":"2021","unstructured":"Barkhof F, Reich DS, Oh J, Oh J, Suthiphosuwan S, Sati P, et al 2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis. Lancet Neurol. Cognitive impairment, the central veign sign, and paramagnetic rim lesions in RIS. Mult Scler J. 2021;27(14):2199\u2013208. https:\/\/doi.org\/10.1177\/13524585211002097.","journal-title":"Mult Scler J"},{"issue":"14","key":"4641_CR53","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1177\/13524585211002097","volume":"27","author":"J Oh","year":"2021","unstructured":"Oh J, Suthiphosuwan S, Sati P, et al Cognitive impairment, the central veign sign, and paramagnetic rim lesions in RIS. Mult Scler J. 2021;27(14):2199\u2013208. https:\/\/doi.org\/10.1177\/13524585211002097.","journal-title":"Mult Scler J"},{"issue":"12","key":"4641_CR54","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/diagnostics10121025","volume":"10","author":"M Castellaro","year":"2022","unstructured":"Castellaro M, Tamanti A, Pisani AI, et al. The use of the central vein sign in the diagnosis of multiple sclerosis: A systematic review and Meta-analysis. Diagnostics (Basel). 2022;10(12):1025. https:\/\/doi.org\/10.3390\/diagnostics10121025.","journal-title":"Diagnostics (Basel)"},{"key":"4641_CR55","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB. Update of the MDS research criteria for prodromal parkinson\u2019s disease. Mov Disord. 2019;34:1464\u201370. https:\/\/doi.org\/10.1002\/mds.27802.","journal-title":"Mov Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04641-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:42:52Z","timestamp":1770896572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4641"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04641-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As the manuscript does not involve clinical studies or patient data, no ethics committee approval or patient consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}